Live Med
  • Live
  • On Demand
    • Congresses
    • Web Events
  • Public
  • Specialty
    • Child Psychiatry
    • Dermatology
    • Forensic Medicine
    • Gynecology
    • Haematology
    • Medical Oncology
    • Neurology
    • Ophthalmology
    • Paediatric
    • Pathology
    • Pulmonology
    • Radiation Oncology
    • Rheumatology
    • Surgery
    • Surgical Oncology
    • Urology
    • Angiosurgery
    • Radiology
    • Allergology
    • Anesthesiology
    • Gastroenterology
    • General Medicine
    • Endocrinology
    • Medical Work
    • Cardiology
    • Social Medicine
    • Cytology
    • Microbiology (Medical Biopathology)
    • Neurosurgery
    • Nephrology
    • Orthopedics
    • Pathology Anatomy
    • Plastic Surgery
    • Nuclear Medicine
    • Physical Medicine and Rehabilitation
    • Thoracic Surgery
    • Children Surgery
    • Psychiatry
    • Otorhinolaryngology
  • Studio
  • Contact Us
  • ABOUT US
  • Support Q&A

LOG IN
REGISTER
LOG INREGISTER

  • EN
  • EL
  • Home
  • Categories
  • Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma
Go Back

Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Select Day

13-04-2022

13-04-2022

Details
6 videos
01 Dr. Lianos - Introduction and objectives of meeting

01 Dr. Lianos - Introduction and objectives of meeting

02 Dr. Papadopoulos & Dr. Kampletsas - Recent updates in mRCC: How must we integrate clinical data in everyday clinical practice in 1L RCC? How do we define the right treatment for the right patient based on guidelines?

02 Dr. Papadopoulos & Dr. Kampletsas - Recent updates in mRC...

03  Dr. Biziota - Could the latest clinical data be a critical factor to a therapeutic decision for sarcomatoid and papillary subgroups?   

03 Dr. Biziota - Could the latest clinical data be a critica...

04 Dr. Kostouros & Dr. Bokas What to do after the 1st line? Which must be the therapeutic selectioncriteria? What is the appropriate 2nd line treatment following single-agent VEGFR-TKI? What is the appropriate 2nd line treatment following IO-IO Combinatio

04 Dr. Kostouros & Dr. Bokas What to do after the 1st line?...

05 Dr. Kaparelou & Dr. Ziogas - AEs associated with therapies (IO Combos-monotherapies) used to treat metastatic renal cancer

05 Dr. Kaparelou & Dr. Ziogas - AEs associated with therapie...

06 Closing Remarks - Discussion all

06 Closing Remarks - Discussion all

  • Pathology
  • Medical Oncology
  • 2022

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

livemed white

Λογότυπο Livemed


© 2026 Live Med | Web Design by Ruler Digital Agency & CnC Tech